RE:Q1 2022 ThoughtsI don't think anyone here is under any illusion in believing that Q1 2022 will be higher than Q1 2021. It won't. Q1 2021 were incredible numbers, yet they never got priced into the stock because the view was it was nearly all covid money and little AI. So by those standards, even with less revenue the reaction should be better because we know the AI and Tech will be higher. Isn't that what naysayers want to see, growth in AI?
Prior to the year-end financial release DM had a 12 month trailing revenue of $46 million. After the year-end financial release they increased that 12 month trailing revenue to $49 million which is averaging a little less than $12.5 million per quarter.
So my feeling is if they can maintain that average that would be an outstanding Q1! However, I think it will be less, but still fantastic if they can achieve anything around $10 million. This lines up with your numbers below. The revenue stream will fluctuate from one quarter to the next. Medi-call will eventual add more and more to that revenue stream, as could potential AI contracts in their various verticals. Right now it's too difficult to predict AI revenues for the year. It only takes one very large AI contract to warp the Q over Q AI and tech revenues and the potential year-end revenues. In these early months of 2022, I'm hoping the company can continue to generate revenue that can maintain that $46-49 million trailing revenue, until the other verticals can start adding to the bottomline. Even that could be a little optimistic, but I can only base it on what we have seen. Not enough information at this time to predict anything more.
swyint123888 wrote: Q4 2021 AI revs - 2,700,000
Q1 2022 AI revs - 3,750,000
Q4 total revs 2020 - 4,750,000
Q4 total revs 2021 - 8,729,000
Q4 2021 total revs break down as such 8,729,000 total - 2,700,000 AI = 6,029,000 covid revs for Q4 2021 with only 14,202 test done in Dec, we don't know Oct or Nov
Jan Feb and Mar came in at 19,446,23,655 and 25,333.....if priced the same in Q1 as Q4 our Q1 2022 revs may be higher than my revised lower number of 10 - 12 million.....much more testing done than Dec for sure.....19 million from 2021 could be attainable.....hopefully Q1 2022 has some NDA and auto renewal revs, Q4 had none so good odds Q1 2022 might have some.
Anyways another decent report in the next month and the uplist, be nice to uplisted with analyst coverage and a strong buy rating